Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2022
15 01 2022
Historique:
received:
24
06
2021
revised:
01
10
2021
accepted:
05
11
2021
pubmed:
12
11
2021
medline:
19
2
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
As noninvasive biomarkers are an important unmet need for neuroendocrine neoplasms (NEN), biomarker potential of genome-wide molecular profiling of plasma cell-free DNA (cfDNA) was prospectively studied in patients with NEN. Longitudinal plasma samples were collected from patients with well-differentiated, metastatic gastroenteropancreatic and lung NEN. cfDNA was subjected to shallow whole-genome sequencing to detect genome-wide copy-number alterations (CNA) and estimate circulating tumor DNA (ctDNA) fraction, and correlated to clinicopathologic and survival data. To differentiate pancreatic NENs (PNEN) from pancreatic adenocarcinomas (PAAD) using liquid biopsies, a classification model was trained using tissue-based CNAs and validated in cfDNA. One hundred and ninety-five cfDNA samples from 43 patients with NEN were compared with healthy control cfDNA ( Sequential genome-wide profiling of plasma cfDNA is a novel, noninvasive biomarker with high specificity for diagnosis, prognosis, and follow-up in metastatic NENs.
Identifiants
pubmed: 34759042
pii: 1078-0432.CCR-21-2291
doi: 10.1158/1078-0432.CCR-21-2291
pmc: PMC9401546
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-349Commentaires et corrections
Type : CommentOn
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
NPJ Genom Med. 2018 Jul 20;3:18
pubmed: 30062048
Endocr Relat Cancer. 2019 Mar 01;26(3):R109-R130
pubmed: 32022503
Neuroendocrinology. 2020;110(11-12):891-898
pubmed: 31658459
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Endocr Relat Cancer. 2018 Jan;25(1):R11-R29
pubmed: 29066503
Am J Surg Pathol. 2016 Sep;40(9):1192-202
pubmed: 27259015
Crit Rev Oncol Hematol. 2020 Nov;155:103109
pubmed: 33049662
Cancers (Basel). 2020 Jun 04;12(6):
pubmed: 32512761
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Front Genet. 2021 May 13;12:654887
pubmed: 34054918
Clin Chem. 2017 Feb;63(2):503-512
pubmed: 27974384
Neuroendocrinology. 2019;108(1):26-36
pubmed: 30282083
Endocr Relat Cancer. 2019 Jan 1;26(1):1-12
pubmed: 30021865
Rev Endocr Metab Disord. 2019 Sep;20(3):333-351
pubmed: 31368038
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Genome Med. 2020 Apr 21;12(1):35
pubmed: 32317009
Mol Oncol. 2020 Sep;14(9):1966-1977
pubmed: 32593194
Minerva Endocrinol. 2019 Dec;44(4):378-386
pubmed: 30991795
Ann Oncol. 2021 Apr;32(4):522-532
pubmed: 33359547
Lancet Oncol. 2015 Sep;16(9):e435-e446
pubmed: 26370353
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
J Pathol. 2017 Mar;241(4):488-500
pubmed: 27873319
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Oncotarget. 2020 May 12;11(19):1749-1757
pubmed: 32477464
Nature. 2010 Apr 15;464(7291):993-8
pubmed: 20393554
Ann Oncol. 2020 Feb;31(2):202-212
pubmed: 31959337
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Ann Oncol. 2016 Apr;27(4):746-7
pubmed: 26712902
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
BMC Cancer. 2020 Apr 7;20(1):291
pubmed: 32264863
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Nat Rev Endocrinol. 2018 Nov;14(11):656-669
pubmed: 30158549
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Res. 2012 Oct;22(10):1995-2007
pubmed: 22637570
Br J Cancer. 2016 Mar 15;114(6):650-8
pubmed: 26978006
Front Oncol. 2018 Nov 01;8:467
pubmed: 30443491
Cancer Metastasis Rev. 2016 Sep;35(3):347-76
pubmed: 27392603
J Clin Invest. 2013 Jun;123(6):2502-8
pubmed: 23676460